These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3598230)

  • 1. Capnocytophaga species: increased resistance of clinical isolates to serum bactericidal action.
    Wilson ME; Jonak-Urbanczyk JT; Bronson PM; Dudas KC; Apicella MA; Genco RJ
    J Infect Dis; 1987 Jul; 156(1):99-106. PubMed ID: 3598230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of Capnocytophaga species to bactericidal properties of human serum.
    Wilson ME; Burstein R; Jonak-Urbanczyk JT; Genco RJ
    Infect Immun; 1985 Oct; 50(1):123-9. PubMed ID: 4044029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capnocytophaga species: infections in nonimmunocompromised and immunocompromised hosts.
    Parenti DM; Snydman DR
    J Infect Dis; 1985 Jan; 151(1):140-7. PubMed ID: 3965585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human complement activation by purified Capnocytophaga exopolysaccharide. Measurement by radioimmunoassay.
    Bolton RW; Dyer JK
    J Periodontal Res; 1986 Nov; 21(6):634-9. PubMed ID: 2947996
    [No Abstract]   [Full Text] [Related]  

  • 5. Capnocytophaga infection: a risk in the immunocompromised host.
    Rummens JL; Verfaillie C; Louwagie A; Boelaert J; Van Landuyt HW
    Acta Clin Belg; 1984; 39(2):109-13. PubMed ID: 6741389
    [No Abstract]   [Full Text] [Related]  

  • 6. Isolation and partial characterization of a genus common antigen and species specific antigen of Capnocytophaga.
    Murayama Y; Mashimo PA; Tabak LA; Levine MJ; Ellison SA
    Jpn J Med Sci Biol; 1982 Aug; 35(4):153-70. PubMed ID: 6185710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bactericidal activity of normal human serum against Enterobacteriaceae rods with lipopolysaccharides possessing O-antigens composed of mannan.
    Tichaczek-Goska D; Witkowska D; Cisowska A; Jankowski S; Hendrich AB
    Adv Clin Exp Med; 2012; 21(3):289-99. PubMed ID: 23214191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and preliminary characterization of a lectinlike protein from Capnocytophaga gingivalis (emended).
    Kagermeier A; London J
    Infect Immun; 1986 Feb; 51(2):490-4. PubMed ID: 3943898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell mitogenicity and IL-1 beta production of lipopolysaccharides from various Capnocytophaga strains.
    Kim SJ; Kato T; Naito Y; Hirai K; Choi JI; Takazoe I; Okuda K
    Bull Tokyo Dent Coll; 1994 May; 35(2):79-83. PubMed ID: 7987967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological activities of Capnocytophaga cellular components.
    Murayama Y; Muranishi K; Okada H; Kato K; Kotani S; Takada H; Tsujimoto M; Kawasaki A; Ogawa T
    Infect Immun; 1982 Jun; 36(3):876-84. PubMed ID: 7095853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and chemical comparison of butanol- and phenol-water extracted lipopolysaccharide from Capnocytophaga sputigena.
    Poirier TP; Mishell R; Trummel CL; Holt SC
    J Periodontal Res; 1983 Sep; 18(5):541-57. PubMed ID: 6227738
    [No Abstract]   [Full Text] [Related]  

  • 12. Capnocytophaga: new genus of gram-negative gliding bacteria. III. Physiological characterization.
    Socransky SS; Holt SC; Leadbetter ER; Tanner AC; Savitt E; Hammond BF
    Arch Microbiol; 1979 Jul; 122(1):29-33. PubMed ID: 518236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of Capnocytophaga canimorsus to killing by human complement and polymorphonuclear leukocytes.
    Shin H; Mally M; Meyer S; Fiechter C; Paroz C; Zaehringer U; Cornelis GR
    Infect Immun; 2009 Jun; 77(6):2262-71. PubMed ID: 19307219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective pressures and lipopolysaccharide subunits as determinants of resistance of clinical isolates of gram-negative bacilli to human serum.
    Porat R; Johns MA; McCabe WR
    Infect Immun; 1987 Feb; 55(2):320-8. PubMed ID: 3804440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular fatty acids of Capnocytophaga species.
    Dees SB; Karr DE; Hollis D; Moss CW
    J Clin Microbiol; 1982 Nov; 16(5):779-83. PubMed ID: 7153332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capnocytophaga keratitis.
    Roussel TJ; Osato MS; Wilhelmus KR
    Br J Ophthalmol; 1985 Mar; 69(3):187-8. PubMed ID: 3978064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Swarming growth and resistance of Proteus penneri and Proteus vulgaris strains to normal human serum.
    Kwil I; Kaźmierczak D; Różalski A
    Adv Clin Exp Med; 2013; 22(2):165-75. PubMed ID: 23709372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro immunosuppression mediated by an extracellular polysaccharide from Capnocytophaga ochracea. Influence of macrophages.
    Bolton RW; Kluever EA; Dyer JK
    J Periodontal Res; 1985 May; 20(3):251-9. PubMed ID: 3160840
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro killing of oral Capnocytophaga by granule fractions of human neutrophils is associated with cathepsin G activity.
    Miyasaki KT; Bodeau AL
    J Clin Invest; 1991 May; 87(5):1585-93. PubMed ID: 2022730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capnocytophaga spp. involvement in bone infections: a review.
    Piau C; Arvieux C; Bonnaure-Mallet M; Jolivet-Gougeon A
    Int J Antimicrob Agents; 2013 Jun; 41(6):509-15. PubMed ID: 23642766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.